Nutrien Ltd (NTR) Stock Price Today
Aura AI Summary
Key Stats
- $33.89BMarket Cap
- 2,589,924Volume
- Basic MaterialsSector
- $83.9452W High
- $53.6452W Low
- 60 DaysTypical Hold Time
- $45.70BEnterprise Value
- 3.09%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Nutrien Ltd (NTR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Nutrien Ltd has traded between a low of $53.64 and a high of $83.94, highlighting its annual price range. Buy and sell Nutrien Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Most Recent News
Basilea presents new data on antifungals fosmanogepix, isavuconazole, and antibiotic ceftobiprole at IDWeek 2026
Basilea Pharmaceutica announced new clinical and activity data for its antifungal drugs fosmanogepix and isavuconazole, as well as the antibiotic ceftobiprole, to be presented at IDWeek 2026 in Washington D.C. Highlights include pediatric data from f...

Gainsight launches AI-native Atlas managing $75M ARR and new value-based pricing for customer retention.
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...

Oculis to present new Phase 2 biomarker data on Privosegtor for optic neuritis at ACTRIMS-ECTRIMS 2026
Oculis Holding AG will present new biomarker analyses from its Phase 2 ACUITY trial of Privosegtor, a potential neuroprotective therapy for optic neuritis, at the 10th Joint ACTRIMS-ECTRIMS Meeting in October 2026. The data focus on plasma neurofilam...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.